Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8642-8650

  Huntoon, Catherine J ^a   Nye, Monica D ^a   Geng, Liyi ^a   Peterson, Kevin L ^a   Flatten, Karen S ^a   Haluska, Paul ^a   Kaufmann, Scott H ^a   Karnitz, Larry M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; HEAT SHOCK PROTEIN 90; LATS1 PROTEIN; LATS2 PROTEIN; RADICICOL; REGULATOR PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL GROWTH; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TISSUE GROWTH; TUMOR CELL; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE II AS TOPIC; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 78449273417     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1345     Document Type: Article

References (50)

1. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005; 10:137-49.
2. Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9:1479-92.
3. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007;8:613-21.
4. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008;20:638-46.
5. Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17:2054-60.
6. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130: 1120-33.
7. Wang K, Degerny C, Xu M, Yang XJ. YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 2009;87:77-91.
8. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/ Yes-associated protein localized in the cytoplasm. Genes Dev 2001;15:1229-41.
9. Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.
10. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999;21:182-6.
11. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005;11:1380-5.
12. Jiang Z, Li X, Hu J, et al. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006;56:450-8.
13. Jimenez-Velasco A, Roman-Gomez J, Agirre X, et al. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 2005;19:2347-50.
14. Hisaoka M, Tanaka A, Hashimoto H. Molecular alterations of h-warts/ LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest 2002;82:1427-35.
15. Cooke IE, Shelling AN, Le Meuth VG, Charnock ML, Ganesan TS. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer 1996;15:223-33.
16. Mazurenko N, Attaleb M, Gritsko T, et al. High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep 1999;6:859-63.
17. Theile M, Seitz S, Arnold W, et al. A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene 1996;13:677-85.
18. Noviello C, Courjal F, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion. Clin Cancer Res 1996;2:1601-6.
19. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16: 425-38.
20. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A 2010;107:1437-42.
21. Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A 2010;107:1431-6.
22. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009;22:1519-26.
23. Seidel C, Schagdarsurengin U, Blumke K, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-71.
24. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
25. Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL. Multiple micro-alterations detected at high frequency in oral cancer. Cancer Res 2005;65:7561-7.
26. Bashyam MD, Bair R, Kim YH, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 2005;7:556-62.
27. Hermsen M, Alonso Guervos M, Meijer G, et al. Chromosomal changes in relation to clinical outcome in larynx and pharynx squamous cell carcinoma. Cell Oncol 2005;27:191-8.
28. Lambros MB, Fiegler H, Jones A, et al. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol 2005;205:29-40.
29. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39:1582-9.
30. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-61.
31. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405-10.
32. Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68:2592-8.
33. Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008;28:2426-36.
34. Arlander SJ, Eapen AK, Vroman BT, et al. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7.
35. Chini CC, Chen J. Repeated phosphopeptide motifs in human Claspin are phosphorylated by Chk1 and mediate Claspin function. J Biol Chem 2006;281:33276-82.
36. Friedman HS, Dolan ME, Kaufmann SH, et al. Elevated DNA polymerase α, DNA polymerase β, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. CancerRes1994;54:3487-93.
37. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66.
38. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001;61:2945-52.
39. Arlander SJ, Felts SJ, Wagner JM, et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006;281:2989-398.
40. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 2000;97:10832-7.
41. Basso AD, Solit DB, Chiosis G, et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277:39858-66.
42. Schulte TW, Akinaga S, Soga S, et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998;3:100-8.
43. Rodina A, Vilenchik M, Moulick K, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 2007;3:498-507.
44. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940-6.
45. Hergovich A, Cornils H, Hemmings BA. Mammalian NDR protein kinases: from regulation to a role in centrosome duplication. Biochim Biophys Acta 2008;1784:3-15.
46. Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res 2008;68:2789-94.
47. Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Invest Drugs 2009;18:861-8.
48. Yano A, Tsutsumi S, Soga S, et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A 2008;105:15541-6.
49. Koga F, Xu W, Karpova TS, et al. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 2006;103:11318-22.
50. Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-38.